GlobeNewswire·Nov 11, 2026, 4:05 PM ET

SpyGlass Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Updates

SpyGlass Pharma acquired Advanced Vision Science, Inc. (AVS) for approximately $13 million in cash to secure scalable commercial intraocular lens (IOL) manufacturing capacity.
The company announced four-year follow-up data from the first-in-human study of the BIM-IOL System, showing a 37% reduction in mean intraocular pressure & 86% of patients remaining off topical IOP-lowering drops.
Phase 3 registrational trial enrollment for the BIM-IOL System remains on track with completion expected in 2027.
First implantations were completed in the first-in-human trial of the Bimatoprost-Drug Ring System (BIM-DRS), a non-IOL-based system designed to deliver up to seven years of bimatoprost.
Cash, cash equivalents & short-term investments totaled $215.8 million as of September 30, 2026, sufficient to fund operations through 2028.
Research & development expenses increased to $10.0 million in Q3 2026 from $8.1 million in the prior year period due to clinical personnel hiring & trial enrollment.
General & administrative expenses rose to $16.2 million in Q3 2026 from $3.0 million in the prior year period due to higher professional service fees & personnel costs.
The company reported a net loss of $24.3 million, or $0.73 per share, for the third quarter of 2026.